Article By:
The Fly
Sunday, February 11, 2024 2:20 PM EDT
Kyverna Therapeutics raised almost $320 million in its initial public offering, which was priced above the marketed range. Backed by Gilead Sciences, the company's offering was the second largest for a drug developer this year.
Gilead Crohn's Treatment Is Not The Solution To GLD Revenue Issues
I have to agree with your assessment on $GILD. Do you know anything about $VBIO? I read a promising article here about their having a major breakthrough in #Crohn's research.
www.talkmarkets.com/.../interview-with-vitality-biopharma-inc
Not a lot of info on the company though.
Gilead Crohn's Treatment Is Not The Solution To GLD Revenue Issues
I think $GILD will rebound. This isn't the only product they have in their pipeline.
Gilead Crohn's Treatment Is Not The Solution To GLD Revenue Issues
I've been rather disappointed with #Gilead myself. After reading your article, I'm planning to offload some $GILD.
Gilead Sciences Receives Canadian Approval For HIV Drug
The opening up of this market for #GileadSciences should bode well for the stock $GILD.
Gilead Sciences: Cheap Growth Or Value Trap?
Excellent analysis, you have effectively convinced me to change my position on #Gilead. $GILD
3 Cult Stocks To Avoid In 2015
Great article and glad to read the reasoning to consider $GILD as a safer investment short, mid and long term.
3 Cult Stocks To Avoid In 2015
Sorry all, thanks for the clarification. My bad! Now that I've read it through, it all makes total sense. $GILD, $BAC, $WFM, and $VA are my plays for 2015.
3 Cult Stocks To Avoid In 2015
I'd say this is a minority view, I've seen several others stating that $GILD was a stock to buy this year.